The global Progressive Fibrosing Interstitial Lung Disease market is currently valued at US$ 4742.2 Million in 2023 and is anticipated to expand at a CAGR of 6.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 8654.1 Million by 2033.
The progressive fibrosing interstitial lung disease market is anticipated to increase due to factors such as increased awareness of PF-ILD along with the expected launch of emerging therapies during the forecast period (2023 to 2033).
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4742.2 Million |
| Projected Forecast Value (2033) | US$ 8654.1 Million |
| Global Growth Rate (2023 to 2033) | 6.2% CAGR |
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.
The type-specific segmentation majorly includes Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and ILDs.
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), are key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of the FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.
PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth
Major factors driving the global progressive fibrosing interstitial lung disease treatment market are an increase in the incidence of lung infections, a surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.
Also, the increasing awareness regarding interstitial lung disease treatment among people, availability of cost-effective drugs in the market, and high prevalence of viral infection-causing lung disorder across the globe is expected to be the key factor driving the growth of progressive fibrosing interstitial lung disease treatment market.
The global progressive fibrosing interstitial lung disease treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.
The adoption of Inorganic Strategies by the Market Players is Expected to Drive Market Growth During the Forecast Period.
The increasing number of partnerships by key players is expected to boost the growth of the global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into a partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).
High Expenditures Associated with Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Research and Development
Although the progressive fibrosing interstitial lung disease treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.
The high expense of therapies has severely hindered their widespread acceptance, particularly in underdeveloped nations. Such high treatment costs are also a subject of worry in developed nations, as many treatments may not be appropriately reimbursed, raising the patient's out-of-pocket expenditures dramatically.
Some side effects after the consumption of anti-inflammatory drugs will also hinder the growth of the progressive fibrosing interstitial lung disease market. All these factors are expected to derail the progress of the progressive fibrosing interstitial lung disease treatment market.
Many drugs have been withdrawn due to clinical challenges in later stages, implying that current emerging drugs may fail and clinical development failure weakens the emerging pipeline. This will disrupt progressive fibrosing interstitial lung disease treatment market growth.
Other factors such as a lack of sensitive clinical outcomes, suitable biomarkers, and difficulty in recruiting subjects, resulting in project delays or cancellations, are hindering the growth of the progressive fibrosing interstitial lung disease treatment market.
Principal Consultant
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 6.0% during the forecast period.
The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American interstitial lung disease treatment market in the years to come.
The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted for by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
Growing Prevalence of Lung-Related Disorders to Boost the Growth of the Market
Europe is expected to have the second maximum market share of the progressive fibrosing interstitial lung disease treatment market due to the high number of people suffering from COPD and asthma in the region.
Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
In addition, technologically advanced healthcare facilities are contributing to the growth of the market. Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, Europe is expected to possess a 56.7% market share in 2023.
| Countries | CAGR |
|---|---|
| United Kingdom | 6.0% |
| India | 5.6% |
| South Korea | 5.7% |
| China | 5.8% |
| United States of America | 6.1% |
Corticosteroids Segment to Generate Significantly High Revenue
On the basis of drug type progressive fibrosing interstitial lung disease (PFILD) treatment market is classified into Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, and Others. Among these corticosteroids registers the highest demand in the progressive fibrosing interstitial lung disease treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. Corticosteroids, except nintedanib and pirfenidone, are commonly used as first-line therapies for ILDs other than IPF. Except for acute exacerbations, international guidelines for IPF treatment strongly recommend corticosteroid monotherapy.
The corticosteroids segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 5.9% over the forecast period 2022to2023.
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 65.5%. The growth of the segment is attributed to the increasing prevalence of Progressive Fibrosing Interstitial Lung Disease (PFILD) and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to Interstitial Lung Disease for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
How do New Entrants Contribute to the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the progressive fibrosing interstitial lung diseases treatment market.
Some of the start-ups in the progressive fibrosing interstitial lung diseases treatment market include-
Some of the key players present in the global progressive fibrosing interstitial lung diseases treatment markets are Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, GNI-EPS Pharmaceuticals, Inc. and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 6.2% from 2023 to 2033 |
| Expected Market Value (2023) | US$4742.2 Million |
| Projected Forecast Value (2033) | US$ 8654.1 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The incidence of diabetic foot ulcers in diabetics and the increasing prevalence of chronic wounds drive market growth.
The market is forecast to register a CAGR of 6.2% through 2033.
Some key players in the global market are Boehringer Ingelheim, Bristol-Myers Squibb, and FibroGen.
The market is estimated to reach US$ 8,654.1 million by 2033.
High expenditures associated with progressive fibrosing interstitial lung disease (PFILD) treatment research and development limit growth.
The high prevalence of the disease, together with the presence of many leading market players in the region, is expected to boost the growth.
1. Executive Summary | Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Corticosteroids 5.3.2. Immune Suppressing 5.3.3. Anti-Fibrotic Medication 5.3.4. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Type 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Type 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Type 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Type 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Type 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Type 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Type 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Type 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Type 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Type 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channe 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Type 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Type 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Type 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Type 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Type 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Type 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Type 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Type 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Type 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Type 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Type 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Type 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Type 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Boehringer Ingelheim 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Bristol-Myers Squibb 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. FibroGen 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Hoffmann-La Roche Ltd 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Pliant Therapeutics, Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. United Therapeutics 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Vicore Pharma AB 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Avalyn Pharmaceuticals 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Beijing Continent Pharmaceutical 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. GNI-EPS Pharmaceuticals, Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market
